Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance
Summary
In recent years, there has been increased focus on cognitive side effects of sleep-inducing medications that may contribute to unusual behavior during unexpected awakenings during the night. Concerns regarding these side effects have led to a class Food and Drug Administration (FDA) warning for all sleep-inducing medications. Almorexant is an experimental sleep-inducing medication in a new class of medications that is being extensively developed by multiple pharmaceutical companies. Medications in this class block wake/arousal centers in the brain that function with proteins called hypocretins. The goal of this study is to evaluate the impact on cognitive performance of almorexant vs. zolpidem (an approved sleep aid) or placebo.
Timeline
- Start
- 2011-05
- Primary completion
- 2014-07
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Zolpidem | Small molecule | 10 mg | — |
| Subject | almorexant | Small molecule | 100 mg | — |
| Subject | almorexant | Small molecule | 200 mg | — |
Indications
No indication recorded.